Publisher： Karger
E-ISSN： 2296-5262|22|4|269-280
ISSN： 2296-5270
Source： Oncology Research and Treatment, Vol.22, Iss.4, 1999-09, pp. : 269-280
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
; (c) modifications of dose intensity with either intraperitoneal therapy or high-dose chemotherapy with peripheral stem cell support. Future studies will have to focus on how to maintain the high remission rates achieved with primary therapy and translate them into long-term survival.
Related content
State-of-the-Art First-Line Treatment of Ovarian Cancer
Oncology Research and Treatment, Vol. 26, Iss. 5, 2003-11 ,pp. :
Access to resources
Recommend
Irinotecan (CPT-11) and Cisplatin as First-Line Chemotherapy for Advanced Ovarian Cancer
Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. :
Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast Cancer
Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. :
First-Line Chemotherapy with Irinotecan plus Capecitabine for Advanced Colorectal Cancer
Oncology, Vol. 66, Iss. 5, 2004-09 ,pp. :
Oncology, Vol. 58, Iss. 1, 2000-01 ,pp. :